07.05.2013 - Spanish diagnostics specialist STAT-Diagnostica has secured €17m in Series B financing.
The Barcelona-based specialist for decentralised testing said it will use the proceeds to complete development of the company’s Near Patient Testing diagnostic system Diagcore and clinical validation of its first products. Led by new investor Kurma Life Sciences Partners, the round also drew participation from new investors Idinvest, Boehringer Ingelheim Venture Fund, and, Caixa Capital Risc, the venture capital division of “la Caixa” as well as existing investors Ysios Capital and Axis.
Founded in 2010, STAT-Diagnostica develops Near Patient Testing systems that simplify and reduce time to results in the growing markets of molecular diagnostics and immunodiagnostics. Its Diagcore® platform enables multiplex qPCR and immundiagnostic analyses in 15 to 30 minutes per run. The company announced that its first testing cartridges will be directed at infectious disease detection, antibiotic resistance determination and detection of biomarkers in critically ill patients.
"The Series B financing is a significant milestone that will support our preparation for a European market launch in 2015,” said Jordi Carrera, CEO and co-founder of STAT-Diagnostica. As part of the Series B financing, Ysios Capital significantly increased its investment in STAT-Diagnostica to become the company’s largest shareholder.
12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.
26.05.2015 The Finnish Medicines Agency Fimea has joined the Dutch MEB in its stance on the interchangeability of biosimilars. The Fimea now sees physician-driven switching of biologics as unproblematic.
02.06.2015 After disappointing Phase III results for immunotherapy tasquinimod and the subsequent discontinuation of the prostrate cancer drug, Swedish Active Biotech is now severely downsizing its operations.
20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).
SuperScript® III Reverse Transcriptase (RT) is a proprietary mutant of SuperScript® II RT that is active at 50°C and has a half-life of 220 minutes, providing increased specificity with gene-specific primers (GSPs) and the highest cDNA yield of all RTs. more